| Advances in covalent kinase inhibitors A Abdeldayem, YS Raouf, SN Constantinescu, R Moriggl, PT Gunning Chemical Society Reviews 49 (9), 2617-2687, 2020 | 261 | 2020 |
| PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia JM Gawel, AE Shouksmith, YS Raouf, N Nawar, K Toutah, S Bukhari, ... European Journal of Medicinal Chemistry 201, 112411, 2020 | 43 | 2020 |
| Characterization of conformationally constrained benzanilide scaffolds for potent and selective HDAC8 targeting MM Hassan, J Israelian, N Nawar, G Ganda, P Manaswiyoungkul, ... Journal of Medicinal Chemistry 63 (15), 8634-8648, 2020 | 41 | 2020 |
| Identification and characterization of AES-135, a hydroxamic acid-based HDAC inhibitor that prolongs survival in an orthotopic mouse model of pancreatic cancer AE Shouksmith, F Shah, ML Grimard, JM Gawel, YS Raouf, M Geletu, ... Journal of Medicinal Chemistry 62 (5), 2651-2665, 2019 | 36 | 2019 |
| Development of HDAC inhibitors exhibiting therapeutic potential in T-cell prolymphocytic leukemia K Toutah, N Nawar, S Timonen, H Sorger, YS Raouf, S Bukhari, J von Jan, ... Journal of Medicinal Chemistry 64 (12), 8486-8509, 2021 | 34 | 2021 |
| Class I/IIb-selective HDAC inhibitor exhibits oral bioavailability and therapeutic efficacy in acute myeloid leukemia AE Shouksmith, JM Gawel, N Nawar, D Sina, YS Raouf, S Bukhari, L He, ... ACS Medicinal Chemistry Letters 11 (1), 56-64, 2019 | 27 | 2019 |
| Discovery of HDAC6-selective inhibitor NN-390 with in vitro efficacy in group 3 medulloblastoma N Nawar, S Bukhari, AA Adile, Y Suk, P Manaswiyoungkul, K Toutah, ... Journal of Medicinal Chemistry 65 (4), 3193-3217, 2022 | 23 | 2022 |
| Unique molecular interaction with the histone deacetylase 6 catalytic tunnel: Crystallographic and biological characterization of a model chemotype OO Olaoye, PR Watson, N Nawar, M Geletu, A Sedighi, S Bukhari, ... Journal of Medicinal Chemistry 64 (5), 2691-2704, 2021 | 22 | 2021 |
| Discovery of YSR734: A covalent HDAC inhibitor with cellular activity in acute myeloid leukemia and Duchenne muscular dystrophy YS Raouf, A Sedighi, M Geletu, GA Frere, RG Allan, N Nawar, ... Journal of Medicinal Chemistry 66 (24), 16658-16679, 2023 | 8 | 2023 |
| Covalent inhibitors: To infinity and beyond YS Raouf Journal of Medicinal Chemistry 67 (13), 10513-10516, 2024 | 5 | 2024 |
| Targeting histone deacetylases: Emerging applications beyond cancer YS Raouf Drug Discovery Today, 104094, 2024 | 4 | 2024 |
| DockCADD: A streamlined In Silico pipeline for the identification of potent Ribosomal S6 Kinase 2 (RSK2) inhibitors M Khedraoui, A Errougui, YS Raouf, A Samadi, S Chtita Scientific African, e02581, 2025 | | 2025 |
| Potential Azo-8-hydroxyquinoline derivatives as multi-target lead candidates for Alzheimer’s disease: An in-depth in silico study of monoamine oxidase and cholinesterase inhibitors FZ Guerguer, B Rossafi, O Abchir, YS Raouf, DB Albalushi, A Samadi, ... PloS one 20 (1), e0317261, 2025 | | 2025 |
| Moroccan natural products for multitarget-based treatment of Alzheimer’s disease: A computational study FZ Guerguer, A Bouribab, EM Karim, M Khedraoui, F Amegrissi, YS Raouf, ... PloS one 20 (1), e0313411, 2025 | | 2025 |
| Exploring Moroccan medicinal plants for anticancer therapy development through in-silico studies A Bouribab, EM Karim, M Khedraoui, O Abchir, A Errougui, YS Raouf, ... Pharmaceuticals 17 (11), 1528, 2024 | | 2024 |
| Slow-binding and covalent HDAC inhibition: A new paradigm? YS Raouf, C Moreno-Yruela JACS Au, 2024 | | 2024 |
| Halogenated phenylsulfonamide hydroxamic acid compounds, compositions and uses thereof as selective hdac6 inhibitors PT Gunning, O Olaoye, K Toutah, AE Shouksmith, JM Shouksmith, ... US Patent App. 17/593,877, 2022 | | 2022 |
| Design and development of novel histone deacetylase inhibitors for the treatment of blood cancers YS Raouf Ph.D. Thesis, University of Toronto, 2022 | | 2022 |
Patrick T. GunningCanada Research Chair and Associate Professor of ChemistryVerifisert e-postadresse på utoronto.ca
